Please assess the completion status of the following clinical trial:

Trial Title: Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spondyloarthritis positive for the ASAS criteria, treated with a first biologic : infliximab ( 5mg/kg intravenously every 8 weeks) or adalimumab (40mg subcutaneously every 2 weeks)~* Active spondyloarthritis definite by ASDAS-CRP \> 2.1 at two successive evaluations while patient was previously responder (ASDAS\<2.1 at least once in the 6th months after beginning of treatment)~* Positivity to anti-drug antibodies (ADAb)~* Consent of the patient~* No contra-indication to another anti-tnf biologic~* affiliation to health insurance~* woman of childbearing age must use an appropriate mean of contraception~Exclusion Criteria:~* Pregnant or breastfeeding woman~* contra-indication to anti-tnf biologic~* patient with known hypersensitivity to any of the excipients~* Severe and uncontrolled opportunistic infection , includins septicemia, tuberculosis, abcess and opportunistic infection~* Evolutive infection, including chronic or localised infection~* Patient with moderate to severe heart failure (NYHA class III/IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- early switch (Type: EXPERIMENTAL): * early switch of monoclonal antibodies anti-TNF~* anti drug antibodies dosage
- therapeutic intensification (Type: EXPERIMENTAL): * therapeutic intensification of monoclonal antibodies anti-TNF~* anti drug antibodies dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).